CN115916747A - 一种并环杂环衍生物及其在医药上的应用 - Google Patents

一种并环杂环衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN115916747A
CN115916747A CN202180035181.XA CN202180035181A CN115916747A CN 115916747 A CN115916747 A CN 115916747A CN 202180035181 A CN202180035181 A CN 202180035181A CN 115916747 A CN115916747 A CN 115916747A
Authority
CN
China
Prior art keywords
alkyl
substituted
halogen
ring
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035181.XA
Other languages
English (en)
Inventor
张晨
赵明亮
叶飞
谷禾
邓华
杨定菊
唐平明
李瑶
倪佳
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN115916747A publication Critical patent/CN115916747A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种通式(I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶，及其中间体和制备方法，以及在制备治疗与JAK激酶活性或表达量相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202180035181.XA 2020-07-01 2021-06-30 一种并环杂环衍生物及其在医药上的应用 Pending CN115916747A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202010616123 2020-07-01
CN2020106161233 2020-07-01
CN202010786985 2020-08-10
CN2020107869850 2020-08-10
CN2020113925222 2020-12-03
CN202011392522 2020-12-03
CN202110487067 2021-05-08
CN2021104870672 2021-05-08
PCT/CN2021/103485 WO2022002118A1 (zh) 2020-07-01 2021-06-30 一种并环杂环衍生物及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN115916747A true CN115916747A (zh) 2023-04-04

Family

ID=79317518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035181.XA Pending CN115916747A (zh) 2020-07-01 2021-06-30 一种并环杂环衍生物及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN115916747A (zh)
TW (1) TW202202498A (zh)
WO (1) WO2022002118A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130110163A (ko) * 2010-08-27 2013-10-08 메르크 파텐트 게엠베하 트리아졸로피라진 유도체들
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
DK3392252T3 (da) * 2011-08-23 2024-01-08 Libertas Bio Inc Pyrimido-pyridazinonforbindelser og deres anvendelse
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN104640863B (zh) * 2012-09-20 2016-06-08 山东亨利医药科技有限责任公司 嘧啶胺衍生物及其制备方法和应用
WO2014051653A1 (en) * 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
CN104098563A (zh) * 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
RS61884B1 (sr) * 2014-10-06 2021-06-30 Signal Pharm Llc Supstituisana aminopurinska jedinjenja, kompozicije koje ih sadrže i postupci za lečenje u kojima se koriste
KR102110573B1 (ko) * 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
CA3018986A1 (en) * 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP6970126B2 (ja) * 2016-06-02 2021-11-24 セルジーン コーポレイション 動物及びヒトの抗マラリア薬
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANTI-TRYPANOSOMA AND ANTI-LEISHMANIA AGENTS FOR ANIMALS AND HUMANS
RU2714206C1 (ru) * 2016-06-30 2020-02-13 Даевунг Фармасьютикал Ко., Лтд. Пиразолопиримидиновые производные в качестве ингибитора киназы
WO2018064545A1 (en) * 2016-09-30 2018-04-05 Sri International Dual clk/cdk1 inhibitors for cancer treatment

Also Published As

Publication number Publication date
WO2022002118A1 (zh) 2022-01-06
TW202202498A (zh) 2022-01-16

Similar Documents

Publication Publication Date Title
AU2018208676B2 (en) Macrocyclic compounds as trk kinase inhibitors
ES2857251T3 (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton
AU2008236649B2 (en) Heteroaryl amide analogues as P2X7 antagonists
AU2007282535B9 (en) Pyrimidine derivative as PI3K inhibitor and use thereof
KR102616249B1 (ko) 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물
US9273028B2 (en) Heterocyclic tyrosine kinase inhibitors
SG189837A1 (en) FURO[3,2-d]PYRIMIDINE COMPOUNDS
US11142526B2 (en) Spirocycle compounds and methods of making and using same
AU2012323399A1 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
US10000497B2 (en) Fused bicyclic heteroaromatic derivatives as kinase inhibitors
WO2020156437A1 (zh) Akt抑制剂
CA3178992A1 (en) N-phenylaminocarbonyl pyridino-, pyrimidino and benzo-tropanes as modulators of gpr65
AU2021290208B2 (en) Tricyclic compounds
CN114057733A (zh) 一种并环杂环衍生物及其在医药上的应用
JP2022510380A (ja) チロシンキナーゼ阻害剤、組成及びその方法
CN115916747A (zh) 一种并环杂环衍生物及其在医药上的应用
TW202045501A (zh) 雙環醚o-糖蛋白-2-乙醯胺基-2-去氧-3-d-哌喃葡萄糖苷酶抑制劑
TW202227418A (zh) 一種雜環衍生物及其在醫藥上的應用
JP7384669B2 (ja) 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物
CN114437063A (zh) 一种氰基衍生物及其在医药上的应用
Ihle et al. Heteroaryl amide analogues as P2X7 antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination